Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 240170
Corporate User License Price USD 10500
Corporate User License Price INR 720510
Site License Price USD 7000
Site License Price INR 480340
Request a Quote

Report Title

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018



Executive Summary

Melanocortin Receptor 4 (MC4R)-Pipeline Review, H2 2018

Summary

Melanocortin Receptor 4 (MC4R)-Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.

Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Infectious Disease and Women's Health which include indications Obesity, Type 2 Diabetes, Alphavirus Infections, Amyotrophic Lateral Sclerosis, Cachexia, Female Hypoactive Sexual Desire Disorder, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis and Prader-Willi Syndrome (PWS).

The latest report Melanocortin Receptor 4 (MC4R)-Pipeline Review, H2 2018, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)

- The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects

- The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Melanocortin Receptor 4 (MC4R)-Overview

Melanocortin Receptor 4 (MC4R)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Melanocortin Receptor 4 (MC4R)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocortin Receptor 4 (MC4R)-Companies Involved in Therapeutics Development

MallInckrodt Plc

Palatin Technologies Inc

Rhythm Pharmaceuticals Inc

Melanocortin Receptor 4 (MC4R)-Drug Profiles

(liraglutide + setmelanotide)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8905-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4-R for Obesity-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4R for Genetic Disorders and Obesity-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocortin Receptor 4 (MC4R)-Dormant Products

Melanocortin Receptor 4 (MC4R)-Discontinued Products

Melanocortin Receptor 4 (MC4R)-Product Development Milestones

Featured News & Press Releases

Jul 23, 2018: Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity

Jun 28, 2018: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

Jun 18, 2018: Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity

Jun 18, 2018: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel (Repository Corticotropin Injection) Studies

Jun 16, 2018: Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)

Jun 14, 2018: Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity

Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide

Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

Jun 01, 2018: Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse Registry for H.P. Acthar Gel

May 09, 2018: Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity

May 07, 2018: Mallinckrodt Provides Facts on H.P. Acthar Gel

Mar 28, 2018: MNK H.P. Acthar Gel CHART Trial Results Alert

Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Mar 19, 2018: Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018

Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by MallInckrodt Plc, H2 2018

Pipeline by Palatin Technologies Inc, H2 2018

Pipeline by Rhythm Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

MallInckrodt Plc

Palatin Technologies Inc

Rhythm Pharmaceuticals Inc

Melanocortin Receptor 4 (MC4R) Therapeutic Products under Development, Key Players in Melanocortin Receptor 4 (MC4R) Therapeutics, Melanocortin Receptor 4 (MC4R) Pipeline Overview, Melanocortin Receptor 4 (MC4R) Pipeline, Melanocortin Receptor 4 (MC4R) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person